Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer (Q24645548)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer	scientific article

Statements

scholarly article

0 references

Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer (English)

0 references

0 references

pharmacodynamics

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hossein Borghaei

1

object named as

Hossein Borghaei

0 references

R Katherine Alpaugh

2

object named as

Katherine Alpaugh

0 references

5

object named as

Corey Langer

0 references

author name string

Gunnar Hedlund

3

0 references

Göran Forsberg

4

0 references

Andre Rogatko

6

0 references

Robert Hawkins

7

0 references

Svein Dueland

8

0 references

Ulrik Lassen

9

0 references

Roger B Cohen

10

0 references

language of work or name

0 references

publication date

1 September 2009

0 references

Journal of Clinical Oncology

0 references

27

0 references

25

0 references

4116-23

0 references

A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

27 September 2017

Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

27 September 2017

Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

27 September 2017

Ligand-targeted therapeutics in anticancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

27 September 2017

Engineering antibodies for therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

27 September 2017

Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

27 September 2017

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

27 September 2017

Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

27 September 2017

Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

27 September 2017

Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

27 September 2017

Immunohistological distribution of 5T4 antigen in normal and malignant tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

27 September 2017

A 72 kD trophoblast glycoprotein defined by a monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

27 September 2017

Superantigens interact with MHC class II molecules outside of the antigen groove.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

30 May 2018

Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

28 November 2018

Enterotoxin residues determining T-cell receptor V beta binding specificity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734423

28 November 2018

Immune response during tumor therapy with antibody-superantigen fusion proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/19636016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/19636016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys

1 reference

https://pubmed.ncbi.nlm.nih.gov/19636016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19636016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/19636016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR

1 reference

https://pubmed.ncbi.nlm.nih.gov/19636016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.20.2515

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24645548&oldid=1915873100"